Active clinical trials for "Body Weight"

Bariatric surgery procedures have consistently been demonstrated to reduce long-term co-morbidities and mortality. Despite its benefits, weight regain is common, usually initiating around two years after the initial procedure, the underlying mechanism often being an enlargement of the anastomosis diameter for the Roux-en-Y gastric bypass. Although a reduction in the anastomosis diameter has been reported in association with endoscopic argon plasma coagulation, to our knowledge this therapy has not been formally tested in a randomized controlled trial. the objective of this study is to conduct a randomized, parallel controlled trial comparing endoscopic argon plasma coagulation to reduce the enlargement of the anastomosis diameter for the Roux-en-Y gastric bypass versus control with an initial diagnostic endoscopic followed by observation. The investigators hypothesize that the argon coagulation arm will achieve greater weight reduction, with a low incidence of adverse events.

The FLOW (First Loss Of Weight) study is designed to assess the effects of repeated administration of GSP3, an investigational product, on body weight. It is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study. FLOW is being conducted in 5 medical centers in Italy, Czech Republic, and Denmark, and will randomize 123 overweight and obese adult males and females to receive either placebo, GSP3 (2.25g), or GSP3 (3.75g) in addition to a hypocaloric diet (-600 kcal/day) for 12 weeks.

To evaluate the efficacy of Litramine in reducing body weight in the context of an energy-restricted diet in overweight and moderately obese subjects

The study aims to randomize 400 participants to 1 of 3 arms: a) a weight stability intervention prior to smoking cessation (Group 1); b) a weight loss intervention prior to smoking cessation (Group 2); or c) a self-guided weight management prior to cessation (Group 3) and to determine the efficacy of the interventions on preventing weight gain at 12 month follow-up. All 3 conditions receive a highly efficacious behavioral smoking cessation program and 6 months of varenicline pharmacotherapy (ChantixTM), the most efficacious medication for smoking cessation.

Dietary protein is a key element of most effective weight loss regimens. This study will investigate the effects of consuming soy protein on body composition and cardiometabolic health within the context of an effective weight loss and maintenance program called the Colorado Diet.

Title: Effect of body weight loading on urinary electrolyte excretion Swedish Title: Effekt av belastning på utsöndring av elektrolyter Study period: Q2-Q3 2017 Study site: The study will be performed at the Institution for Neurology and Physiology, Sahlgrenska Academy, University of Gothenburg. Principal Investigator is John-Olov Jansson, MD, PhD, Professor at Institute of Neuroscience and Physiology, University of Gothenburg Background and study design: Weight reduction can be obtained by decreased appetite or increased metabolism. However, acute weight loss can also be obtained by loss of fluids - for example by increased urinary loss of fluid and salts, so called elctrolytes. Preliminary results from a laboratory lesson for the Master of Science in Medicine program at University of Gothenburg suggest that carrying a 10 kg weight vest could increase urinary excretion of Na+, K+ and Cl-. The purpose of this study is to investigate this further in a more controlled research setting. If confirmed, the results could potentially contribute to the development of potent diuretics or obesity medicines. The study will include 15 healthy volunteers and consist of three study days with about one week between each study day. The study subjects will go through a different study procedure each study day, and a randomized cross-over study design will be used to determine which procedure each day. Procedure 1: Wearing a weight vest with 10 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour. The reason for this is that it has been considered that the effect may be transmitted by weight loading of the lower extremities. Procedure 2: Wearing a weight vest with 1 % of body weight standing for seven hours, as a control for procedure 1, with lower loading. The study subject is allowed to sit for 10 minutes each hour. Procedure 3: Wearing a weight vest with 1 % of body weight sitting for seven hours. This is a procedure with even less loading of the lower extremities than during procedure 2. Urine- and blood samples, as well as heart rate and blood pressure measurements, will be collected during the study days and analyzed in order to address the primary and secondary objectives of the study.

The aim of the study is to test whether wearing a weighted jacket can help improve the balance distortion of patients with neurologic pathologies. The center of mass of the patient will be analyzed in order to determine the direction in which the imbalance is most important. Weights will be placed accordingly in a jacket in order to correct the imbalance. In the experimental group, weights will represent 1.5 to 2% of the patient body mass. In the control group, the investigators will use weights of 200 grams maximum, placed evenly on both sides of the jacket. Patients will wear the jacket for 2 consecutive hours. After wearing the jacket for 2 hours, data similar to those recorded at the beginning of the experiment will be taken again, namely the determination of the center of mass and of the deviations caused by the imbalance. A final series of tests will take place approximately one week after wearing the jacket, to determine if there are any residual effects.

It was proven in a previous clinical study that Glucosanol™ is effective and safe in reducing weight in the overweight and obese. The present study aims at expanding the data concerning the weight management effect of Glucosanol™ in overweight and moderately obese population.

Weight reduction is the most important treatment target in obese women with polycystic ovary syndrome (PCOS), yet it is usually hardly achievable with lifestyle intervention alone. Glucagon-like peptide 1 (GLP-1) receptor agonist (RA) liraglutide was recently approved as an anti-obesity drug but with some limitations, which include high cost and the lack of long-term efficacy and safety data regarding weight reduction. In addition, weight loss achieved with liraglutide is often non-sustainable after treatment cessation. Although DPP-4 inhibitors are weight neutral, they reduced weight regain in animals previously treated with GLP-1 RAs if they were switched to DPP-4 inhibitor rather than placebo. The aim is to evaluate whether DPP-4 inhibitor sitagliptin in combination with metformin reduce body weight regain more effectively than metformin alone in obese PCOS who had been previously treated with liraglutide.

The aim of the present study is to test the effects of a digital meditation intervention and/or a healthy eating intervention in a sample of UCSF employees with overweight and obesity (BMI>=25kg/m2) who report mild to moderate stress. We will randomize UCSF employees to 8-weeks of a digital meditation intervention (using the commercially available application, Headspace), a healthy eating intervention, a digital meditation+healthy eating intervention, or a waitlist control condition.